The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Minimal Toxicities Reported in Extreme Hypofractionated Comparison Trial in Prostate Cancer
October 10th 2016Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.
FDA Grants Priority Review to Daratumumab Triplets for Relapsed Myeloma
October 8th 2016The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
Radiation and TGFβ Inhibition Combo Elicits Activity in Metastatic Breast Cancer
October 7th 2016A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.
Daratumumab Combo Data Published as FDA Considers New Myeloma Indication
October 6th 2016As the FDA considers a supplemental biologics license application for 2 daratumumab-based triplet regimens in multiple myeloma, the results for 1 of the pivotal phase III studies supporting the sBLA have been published in The New England Journal of Medicine.
Optimal Management for NSCLC Patients with Brain Metastases
October 6th 2016A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer with brain metastases to determine the best option for treatment.
Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment
October 6th 2016William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
H-RT Reduces Treatment Time by One-Third in Low-Risk Prostate Cancer
October 5th 2016Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.
Efforts Continue to Refine Use of Checkpoint Inhibitors in NSCLC
October 5th 2016Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.
KRAS-Variant HNSCC Outcomes May Improve With Cetuximab
October 4th 2016Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.
Langer Lends Insight on Burgeoning Lung Cancer Developments, Challenges
October 3rd 2016From optimal therapies for patients with non-driver adenocarcinoma, to studying the biology of squamous cell non–small cell lung cancer, to exploring novel combination regimens, to predicting the risk of mortality, the field of lung cancer is undergoing tremendous changes, explained Corey J. Langer, MD.
EGFR-Targeted Approach Continues to Advance in NSCLC
September 30th 2016Joshua Bauml, MD, discusses the evolution of EGFR-targeted therapies, resistance mutations in patients with non–small cell lung cancer, the evolution of next-generation sequencing, and ongoing trials that could have an impact in this space.
Fewer GI, GU Toxicities With Postoperative Pelvic IMRT in Gynecologic Malignancies
September 29th 2016Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.